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The neutralization of dietary acid with sodium bicarbonate
decreases kidney injury and slows the decline of the
glomerular filtration rate (GFR) in animals and patients with
chronic kidney disease. The sodium intake, however, could
be problematic in patients with reduced GFR. As alkali-
induced dietary protein decreased kidney injury in animals,
we compared the efficacy of alkali-inducing fruits and
vegetables with oral sodium bicarbonate to diminish kidney
injury in patients with hypertensive nephropathy at stage 1
or 2 estimated GFR. All patients were evaluated 30 days after
no intervention; daily oral sodium bicarbonate; or fruits and
vegetables in amounts calculated to reduce dietary acid by
half. All patients had 6 months of antihypertensive control by
angiotensin-converting enzyme inhibition before and during
these studies, and otherwise ate ad lib. Indices of kidney
injury were not changed in the stage 1 group. By contrast,
each treatment of stage 2 patients decreased urinary
albumin, N-acetyl b-D-glucosaminidase, and transforming
growth factor b from the controls to a similar extent. Thus, a
reduction in dietary acid decreased kidney injury in patients
with moderately reduced eGFR due to hypertensive
nephropathy and that with fruits and vegetables was
comparable to sodium bicarbonate. Fruits and vegetables
appear to be an effective kidney protective adjunct to blood
pressure reduction and angiotensin-converting enzyme
inhibition in hypertensive and possibly other nephropathies.
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Developing safe and effective kidney-protective interventions
to slow or stop the progression of established nephropathy is
an important strategy in reducing the incidence of complete
kidney failure. Such interventions will likely have the greatest
benefit in those with no or moderately reduced glomerular
filtration rate (GFR) who comprise the largest cadre of
subjects with chronic kidney disease (CKD).1 Hypertension-
associated nephropathy is the second leading cause of
complete kidney failure in the United States,2 and most of
them with moderately reduced GFR have progressive GFR
decline despite blood pressure (BP) reduction with renin–
angiotensin system inhibition.3,4 Because acid-inducing diets
increased and strategies to reduce dietary acid with oral
alkali- or base-inducing dietary protein decreased kidney
injury in animals with normal GFR,5 and additionally slowed
GFR decline in animals with moderately reduced GFR,6,7 the
largely acid-inducing diets of industrialized societies8 might
mediate progressive GFR decline in those with moderately
reduced GFR due to hypertensive nephropathy. Supporting
this hypothesis, adding oral NaHCO3 to renin–angiotensin
system inhibition ameliorated kidney injury and slowed
estimated GFR (eGFR) decline in subjects with moderately
reduced GFR due to hypertensive nephropathy without
metabolic acidosis.4 Together, these data support the fact that
dietary acid reduction is kidney protective in subjects with
moderately reduced GFR due to hypertensive nephropathy.
Despite its apparent benefits, dietary acid reduction with
NaHCO3 obligates added dietary Na
þ that might worsen
hypertension and/or volume control in subjects with reduced
GFR. Other strategies to reduce dietary acid might be equally
or more kidney protective while limiting added Naþ .
Industrialized society diets are acid-inducing largely because
of a high ratio of acid-inducing to base-inducing proteins,
the latter being mostly fruits and vegetables (FþV).8
Consequently, decreasing dietary acid by adding base-
inducing FþV might decrease kidney injury as effectively
as NaHCO3, but with less added Na
þ . We compared urine
indices of kidney injury in subjects with CKD due to
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hypertensive nephropathy with normal or moderately
reduced eGFR after 30 days of dietary acid reduction with
FþV or oral NaHCO3 (HCO3) to compare the kidney-
protective efficacy of FþV.
RESULTS
Table 1 shows general subject characteristics by group at
baseline. There was no significant difference in age, weight,
systolic BP (Sys BP), or gender proportion among groups.
Subjects with metabolic acidosis were excluded (Materials
and Methods), but P-value for venous plasma total CO2
(TCO2), across all groups, supports slightly, but significantly,
lower plasma TCO2 in CKD 2 than in CKD 1. Nevertheless,
there were no differences in potential renal acid load, a
measure of dietary acid intake,9 or in urine 8 h net acid
excretion (8 h NAE) between CKD 1 and CKD 2. Urine
albumin excretion (Ualb), a general index of the course and
level of kidney injury,10 was not significantly different among
groups. Urine N-acetyl b-D-glucosaminidase excretion
(UNAG), an index of tubulo-interstitial injury,11 was not
different among groups, but CKD 2 had higher urine
excretion of transforming growth factor-b (UTGF), a possible
mediator of hypertensive nephropathy activity,12 than CKD 1.
Table 2 shows net changes in acid–base parameters at 30
days after HCO3, FþV, or no intervention (Time Control).
Venous plasma TCO2 did not change significantly in any
group. Although potential renal acid load did not decrease in
either HCO3 group, potential renal acid load decreased in
CKD 1 FþV and CKD 2 FþV. Each intervention to reduce
dietary acid decreased 8 h NAE in both CKD 1 and CKD 2,
and the net decrease was not significantly different between
respective FþV and HCO3 groups of CKD 1 and CKD 2.
Figure 1 shows box plots for net Ualb change (post–pre) in
the three CKD 1 and CKD 2 groups. Net Ualb change was not
different among the three CKD 1 groups (P¼ 0.201). Net
Ualb for CKD 2 Time Control (9.0±29mg/g Creatinine
(Cr)) was not significantly different from zero (P¼ 0.0564),
but Ualb significantly decreased in CKD 2 HCO3
(14.7±22.2mg/g Cr, Po0.001 versus zero) and CKD 2
FþV (34.3±46.9mg/g Cr, Po0.001 versus zero). Figure 1
also shows that the net Ualb decrease was significantly more
than Time Control in CKD 2 HCO3 (P¼ 0.003) and CKD 2
FþV (Po0.001), and that the net decrease in CKD 2 FþV
was significantly greater than CKD 2 HCO3 (P¼ 0.012).
Figure 2 shows box plots of the net UNAG change
(post–pre) in the three groups of CKD 1 and CKD 2. After 30
days, net UNAG change was not significantly different among
the three CKD 1 groups (P¼ 0.994). On the other hand, net
UNAG significantly increased for CKD 2 Time Control
(0.062±0.136U/g Cr, P¼ 0.006) but significantly decreased
for CKD 2 HCO3 (0.088±0.134U/g Cr, Po0.001) and
CKD FþV (0.080±0.080U/g Cr, Po0.001). Figure 2
shows that the net UNAG decrease was significantly greater
than CKD 2 Time Control in CKD 2 HCO3 (Po0.001) and
CKD 2 FþV (Po0.001), but the net decrease was not
significantly different between CKD 2 HCO3 and CKD 2
FþV (P¼ 0.081).
Figure 3 shows box plots of the net change (post–pre)
of UTGF. After 30 days, UTGF significantly decreased in
CKD 1 Time Control (1.819±3.106 ng/g Cr, P¼ 0.005),
Table 1 | General patient characteristics by group at baseline
CKD1 CKD2
Time Control
(N=27)
HCO3
(N=26)
F+V
(N=26)
Time Control
(N=40)
HCO3
(N=40)
F+V
(N=40) P-value
Males (%) 44.4 50 46.2 47.5 47.5 47.5 0.999
Black/White/Hispanic (%) 29.6/22.2/48.2 34.6/23.1/42.3 34.6/19.2/46.2 62.5/22.5/15.0 62.5/20.0/17.5 62.5/25.0/12.5 0.005
Variable Mean±s.d. Mean±s.d. Mean±s.d. Mean±s.d. Mean±s.d. Mean±s.d.
Age (years) 49.3±9.1 49.9±8.6 49.4±9.6 51.5±8.3 51.2±8.2 51.3±8.5 0.836
Wt (kg) 83.5±2.9 83.4±2.6 83.7±2.2 82.7±2.1 82.8±1.9 82.7±2.8 0.329
Systolic BP (mmHg) 133.9±4.6 133.0±5.7 133.5±5.4 134.3±8.3 134.1±5.8 133.7±8.6 0.985
eGFR (ml/min) 100.3±6.7 101.6±7.3 100.8±8.5 75.6±6.5 75.3±6.1 75.6±6.2 o0.001
Plasma total CO2 (mmol/l) 26.4±1.0 26.4±0.6 26.4±0.8 26.0±0.8 25.9±0.6 25.9±0.8 0.004
Potential renal acid load (mmol/day) 63.9±8.9 62.0±8.8 62.9±14.5 59.3±21.1 64.3±17.7 60.4±19.4 0.756
8-Hour urine net acid excretion (mEq) 24.4±2.5 25.6±4.2 24.7±2.9 24.6±5.7 24.8±5.6 24.6±5.0 0.948
PNa (mEq/l) 139.2±1.7 139.2±1.8 139.1±1.6 139.7±1.7 139.7±1.7 139.6±1.3 0.526
PK (mEq/l) 4.2±0.2 4.2±0.2 4.2±0.2 4.2±0.2 4.2±0.2 4.2±0.2 0.960
Paldo (pg/ml) 60.7±12.2 61.2±12.6 59.6±9.5 93.7±19.8 90.7±6.8 92.5±10.2 o0.001
PET-1 (pg/ml) 3.0±0.3 3.1±0.2 3.0±0.2 4.8±1.1 4.8±0.5 4.8±0.4 o0.001
Ualb (mg/g Cr) 402.1±71.4 396.8±76.8 414.9±78.7 413.6±147.9 419.3±150.8 422.2±151.6 0.966
UNAG (U/g Cr) 2.6±0.3 2.6±0.3 2.5±0.5 2.7±0.4 2.7±0.4 2.7±0.7 0.476
UTGF (ng/g Cr) 42.5±11.5 44.6±12.2 42.5±17.9 63.6±18.0 60.7±6.8 63.8±14.5 o0.001
UET-1 (ng/g Cr) 3.5±0.6 3.7±0.8 3.5±1.7 5.5±1.1 5.7±1.0 5.5±1.2 o0.001
Ualdo (mg/g Cr) 13.3±2.7 13.9±2.4 13.1±2.8 37.4±8.7 32.7±8.4 36.7±8.7 o0.001
UNaV (mmol/g Cr) 74.2±11.5 75.0±11.4 77.4±8.2 71.6±7.9 70.9±10.2 73.0±9.5 0.103
UKV (mmol/g Cr) 35.9±6.3 38.1±6.6 37.6±4.4 38.6±5.5 41.1±6.1 39.5±6.6 0.019
Abbreviations: BP, blood pressure; CKD, chronic kidney disease; Cr, creatinine; eGFR, estimated GFR by the MDRD formula; F+V, 30 days after dietary intervention with fruits +
vegetables; HCO3, 30 days after oral intervention with oral NaHCO3, 0.5mEq/kg bw/day; Paldo, plasma aldosterone excretion; PET, plasma endothelin excretion; PK, plasma
potassium excretion; PNa, plasma sodium excretion; Ualb, urine albumin excretion; Ualdo, urine aldosterone excretion; UET, urine endothelin excretion; UKV, urine excretion
of Kþ ; UNAG, urine N-acetyl b-D-glucosaminidase excretion; UNaV, urine excretion of Naþ ; UTGF, urine excretion of transforming growth factor-b.
P-values for overall (six groups) comparison were presented.
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HCO3 (2.223±2.721 ng/g Cr, Po0.001), and FþV
(2.397±3.403 n/g Cr, P¼ 0.001), but net UTGF decrease
was not significantly different among the three CKD 1 groups
(P¼ 0.783). By contrast, UTGF significantly increased in
CKD 2 Time Control (2.298±6.994 ng/g Cr, P¼ 0.044) but
decreased in HCO3 (6.888±4.953 ng/g Cr, Po0.001) and
FþV (6.483±4.908 ng/g Cr, Po0.001). Figure 3 shows
that net UTGF decrease was significantly greater than CKD 2
Time Control in CKD 2 HCO3 (Po0.001) and CKD 2 FþV
(Po0.001), but the net decrease was not significantly
different between HCO3 and FþV (P¼ 0.751).
Table 3 shows the net change in body weight, Sys BP, and
selected plasma and urine parameters. Body weight did not
change significantly in Time Control and HCO3 groups of
both CKD 1 and CKD 2, but it decreased significantly in both
CKD 1 and CKD 2 groups given FþV. The net body weight
decrease was not significantly different between CKD 1 and
CKD 2 groups given FþV (P¼ 0.062). Similarly, Sys BP did
not change significantly in any Time Control or HCO3 group,
but decreased significantly in both CKD 1 and CKD 2 given
FþV. In contrast to body weight, the net Sys BP decrease was
significantly greater in CKD 2 FþV than in CKD 1 FþV
(P¼ 0.001).
In addition, Table 3 shows the net change in plasma levels
and urine excretion of Naþ (UNaV) and Kþ (UKV). Plasma
Naþ did not change significantly in any group and plasma Kþ
did not change significantly in any CKD 1 group. Although
plasma Kþ did not significantly change in CKD 2 Time
Control and CKD 2 FþV, plasma Kþ decreased slightly but
significantly in CKD 2 group given HCO3, and the net
decrease was greater than CKD 2 Time Control and FþV.
Both UNaV and UKV increased significantly in CKD 1 and
CKD 2 groups given HCO3, and the net increase in CKD 1 and
CKD 2 was significantly greater than their respective Time
Control. UNaV decreased significantly and UKV increased
significantly in both CKD 1 and CKD 2 groups given FþV,
and the net UNaV decrease and the net UKV increase in both
CKD 1 and CKD 2 groups given FþV were significantly
Table 2 | Net change in acid-base data pre- and post-dietary intervention (post–pre), expressed as mean±s.d.
CKD 1 CKD 2
Time Control HCO3 F+V Time Control HCO3 F+V
mean±s.d. mean±s.d. mean±s.d. mean±s.d. mean±s.d. mean±s.d.
Plasma total CO2 (mmol/l) 0.0±1.2 0.0±0.7 0.1±1.1 0.0±0.5 0.1±0.6 0.0±0.4
P-value, pre versus post 0.886 0.935 0.687 0.742 0.387 0.604
Potential renal acid load (mmol/day) 0.1±2.5 0.1±2.7 20.9±10.9*,** 0.2±2.6* 0.0±2.5 21.7±11.9*,**
P-value, pre versus post 0.809 0.865 o0.001 0.688 0.914 o0.001
8-Hour urine net acid excretion (mEq) 0.1±1.1 6.0±4.8* 7.9±5.2*,** 0.3±1.7 7.2±6.0* 8.1±4.6*
P-value, pre versus post 0.751 o0.001 o0.001 0.333 o0.001 o0.001
Abbreviations: CKD, chronic kidney disease; F+V, 30 days after dietary intervention with fruits + vegetables; HCO3, 30 days after oral intervention with oral NaHCO3.
*Po0.05 versus Time Control in change (Post-Pre).
**Po0.05, versus HCO3 in change.
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Figure 1 |Box plots of change of urine albumin (mg)-to-
creatinine (g) ratio (Ualb) for the three groups of subjects
with estimated glomerular filtration rate (eGFR) 490ml/min
(CKD 1) and eGFR 60–90ml/min (CKD 2). CKD, chronic kidney
disease; FþV, subjects given fruitsþ vegetables for 30 days;
HCO3, subjects given oral NaHCO3 daily for 30 days; Time Control,
subjects followed up for 30 days with no further intervention.
*Po0.05 versus Time Control; þPo0.05 versus HCO3.
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Figure 2 |Box plots of change of urine N-acetyl-b-D-
glucosaminidase (U)-to-creatinine (g) ratio (UNAG) for the
three groups of subjects with eGFR 490ml/min (CKD 1) and
eGFR 60–90ml/min (CKD 2). CKD, chronic kidney disease; FþV,
subjects given fruitsþ vegetables for 30 days; HCO3, subjects
given oral NaHCO3 daily for 30 days; Time Control, subjects
followed up for 30 days with no further intervention.
*Po0.05 versus Time Control.
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different from their respective Time Control. The UKV
increase was greater in the respective FþV than in the
HCO3 group for CKD 1 (Po0.001) and CKD 2 (Po0.001).
Table 3 also shows the net change in plasma levels and
urine excretion of endothelin (ET)-1 and aldosterone. Urine
ET-1 excretion (UET), a surrogate of kidney ET-1 levels,13
did not decrease in any CKD 1 group or in CKD Time
Control. By contrast, UET decreased significantly in both
intervention groups of CKD 2, and the net decrease was
significantly greater than CKD 2 Time Control in both CKD
2 intervention groups. Urine aldosterone excretion (Ualdo),
a surrogate of kidney aldosterone levels,7 significantly
decreased in both the intervention groups of CKD 1 and
CKD 2. The net decrease in Ualdo was significantly greater in
both the intervention groups than the respective Time
Controls in both CKD 1 and CKD 2. Although the net
Ualdo decrease was not significantly different between the
two CKD 1 intervention groups, the net Ualdo decrease was
greater in CKD 2 HCO3 than in CKD 2 FþV.
DISCUSSION
Dietary acid reduction with oral NaHCO3 for 5 years
ameliorated kidney injury and slowed GFR decline in CKD
subjects with moderately reduced eGFR due to hypertensive
nephropathy.4 The present studies extend these observations
by showing that (1) 30 days of HCO3 or FþV comparably
decreased kidney injury in subjects with CKD 2 but not with
CKD 1 due to hypertensive nephropathy; and (2) kidney
injury reduction was more evident in CKD 2 than in CKD 1.
The data support the fact that both FþV and NaHCO3 are
kidney-protective adjuncts to reduced Sys BP and angioten-
sin-converting enzyme inhibition in hypertensive and
possibly other nephropathies.
Kidney injury did not change significantly after 30 days of
HCO3 or FþV in CKD 1. By contrast, FþV and NaHCO3
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Figure 3 |Box plots of change of urine transforming growth
factor-b (ng)-to-creatinine (g) ratio (UTGF) for the three
groups of subjects with estimated glomerular filtration rate
(eGFR) 490ml/min (CKD 1) and eGFR 60–90ml/min (CKD 2).
CKD, chronic kidney disease; FþV, subjects given
fruitsþ vegetables for 30 days; HCO3, subjects given oral NaHCO3
daily for 30 days; Time Control, subjects followed up for 30 days
with no further intervention. *Po0.05 versus Time Control.
Table 3 | Change in systolic blood pressure and urine and plasma variables, pre- and post-dietary intervention (Post–Pre),
expressed as means±s.d.
CKD1 CKD2
Time Control HCO3 F+V Time Control HCO3 F+V
mean±s.d. mean±s.d. mean±s.d. mean±s.d. mean±s.d. mean±s.d.
Weight (kg) 0.12±0.73 0.12±0.81 1.82±0.98*,** 0.07±0.81 0.02±0.58 2.31±1.04*,**
P-value, pre versus post 0.389 0.459 o0.001 0.574 0.807 o0.001
Systolic BP (mmHg) 0.1±2.6 0.3±3.0 2.4±2.3*,** 0.5±4.1 0.2±2.9 5.4±4.6*,**
P-value, pre versus post 0.765 0.566 o0.001 0.488 0.749 o0.001
PNa (mEq/l) 0.44±1.34 0.27±1.31 0.54±1.48 0.05±1.36 0.05±1.24 0.03±0.92
P-value, pre versus post 0.097 0.306 0.075 0.817 0.800 0.864
PK (mEq/l) 0.04±0.13 0.02±0.14 0.03±0.14* 0.00±0.10 0.10±0.09* 0.00±0.11**
P-value, pre versus post 0.076 0.574 0.266 40.999 o0.001 0.891
PET-1 (pg/ml) 0.02±0.11 0.16±0.26* 0.11±0.14* 0.02±0.18 0.55±0.30* 0.66±0.34*
P-value, pre versus post 0.323 0.004 o0.001 0.595 o0.001 o0.001
Paldo (pg/ml) 0.04±3.10 3.58±14.71 1.81±1.99 0.93±6.41 18.26±4.48* 6.17±4.98*,**
P-value, pre versus post 0.951 0.226 o0.001 0.362 o0.001 o0.001
UET-1 (ng/g Cr) 0.04±0.16 0.33±1.81 0.23±1.21 0.09±0.45 0.75±0.50* 0.54±0.69*
P-value, pre versus post 0.245 0.359 0.342 0.208 o0.001 o0.001
Ualdo (mg/g Cr) 0.02±0.81 2.15±2.74* 1.48±1.55* 0.73±2.80* 6.96±4.67* 3.16±2.74*,**
P-value, pre versus post 0.906 0.001 o0.001 0.107 o0.001 o0.001
UNaV (mmol/g Cr) 0.60±3.60* 12.40±15.87* 7.52±4.74*,** 1.16±4.83* 5.73±2.65* 8.00±4.32*,**
P-value, pre versus post 0.391 0.001 o0.001 0.136 o0.001 o0.001
UKV (mmol/g cr) 0.85±3.45* 4.56±7.47* 7.75±4.20*,** 0.93±3.54* 4.13±3.18* 10.01±3.10*,**
P-value, pre versus post 0.213 0.005 o0.001 0.106 o0.001 o0.001
Abbreviations: BP, blood pressure; CKD, chronic kidney disease; F+V, 30 days after dietary intervention with fruits+vegetables; HCO3, 30 days after oral intervention with oral
NaHCO3; Paldo, plasma aldosterone excretion; PET, plasma ET excretion; PK, plasma potassium excretion; PNa, plasma sodium excretion; Ualdo, urine aldosterone excretion;
UET, urine endothelin excretion; UKV, urine excretion of Kþ ; UNaV, urine excretion of Naþ .
*Po0.05 versus Time Control in change (post–pre).
**Po0.05, versus HCO3 in change.
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each significantly and comparably decreased kidney injury in
CKD 2. Animals with 2/3 nephrectomy have reduced GFR
without metabolic acidosis, similar to CKD 2, and reduced
dietary acid with base-inducing protein, or with NaHCO3
each decreased kidney injury and slowed GFR decline.6,7 The
2/3 nephrectomy animals had acid retention by microdialysis,
which mediated kidney injury and progressive GFR decline
despite the absence of metabolic acidosis.6,7 Amelioration of
acid retention associated with reduced GFR with either
dietary intervention decreased kidney injury and slowed GFR
decline.6,7 Because CKD 2 subjects without metabolic
acidosis appear to have acid retention14 similar to 2/3
nephrectomy animals, we hypothesize that amelioration of
acid retention with each strategy decreases kidney injury in
CKD 2. Because dietary acid intake and the initial and follow-
up 8 h NAE after 30 days of HCO3 or FþV were not
significantly different, each intervention appears to have
reduced acid retention similarly. Together, the data support
the fact that decreased kidney injury induced by dietary acid
reduction was mediated by amelioration of acid retention
in CKD 2.
Dietary acid reduction with FþV, but not NaHCO3, in
CKD 2 (Table 2) was accompanied by a significant decrease
in Sys BP, which might add cardiovascular protection to
FþV as a potentially kidney-protective intervention. Re-
duced Sys BP with FþV was evident in both CKD 1 and
CKD 2 in subjects starting a vegetarian diet.15 Sys BP
reduction decreases Ualb in primary hypertension16 and the
statistically greater reduction in Ualb in CKD 2 subjects given
FþV compared with NaHCO3 might have been mediated by
Sys BP reduction in CKD 2 subjects given FþV but not
NaHCO3. In addition, lower UNaV in FþV compared with
NaHCO3 and Time Control CKD 2 subjects, consistent with
reduced Naþ intake, might also have contributed to lower
Ualb in CKD 2 subjects given FþV.17 Reduced UNaV and
increased UKV in FþV (Table 3), consistent with reduced
and increased intake of each, respectively, likely mediates this
BP reduction.18,19 In addition, reduced body weight (Table 3)
with FþV might also have contributed.20 Furthermore, the
greater Ualb decrease in CKD 2 than in CKD 1 group given
FþV was associated with greater Sys BP reduction in CKD 2
than in CKD 1 group given FþV. Consequently, greater Sys
BP reduction might have mediated the greater Ualb decrease
in CKD 2 than in CKD 1 group given FþV. Dietary Naþ
reduction decreases Sys BP more in those patients with
reduced than normal GFR,21 and possibly explains greater Sys
BP reduction in CKD 2 than in CKD 1.
Because Kþ depletion increases BP,19 changes in Kþ
balance might also have contributed to differences in Sys BP
among CKD 2 groups. The increased UK in FþV is
consistent with an increase in Kþ -containing foods as
determined from follow-up 3-day diaries in these CKD 2
subjects, and this dietary change would be expected to
promote a decrease in BP.19 By contrast, 3-day diaries showed
no increase in Kþ -containing foods in CKD 2 subjects given
NaHCO3, yet they had increased UK in response to NaHCO3
as observed by others.22 Greater UK in CKD 2 patients given
NaHCO3 combined with a slight but significant decrease in
plasma Kþ (Table 3) might indicate reduced Kþ stores.
Consequently, mild Kþ depletion in CKD 2 given NaHCO3
might have limited or precluded Sys BP reduction in these
CKD 2 subjects, potentially making this strategy for dietary
acid reduction less cardiovascular protective than FþV.
Although no CKD 2 group given FþV experienced an
increase in plasma Kþ , caution is warranted in prescribing
FþV to CKD subjects with lower GFRs.
Urine NAG excretion assessed tubulo-interstitial injury,11
a component of kidney injury that was induced by dietary
acid and ameliorated by dietary alkali and by diets containing
base-inducing protein in animals with moderately6,7 and
severely23 reduced GFR. Similarly, dietary alkali ameliorated
UNAG in subjects with CKD due to hypertensive nephro-
pathy with moderately4 and severely 24 reduced eGFR. The
UNAG data support that neither FþV nor NaHCO3
decreased tubulo-interstitial injury in CKD 1. By contrast,
UNAG data in CKD 2 support that tubulo-interstitial injury
worsened after 30 days of no intervention, but that FþVand
NaHCO3 each decreased tubulo-interstitial injury after 30
days. Unlike Ualb, net UNAG decrease was not significantly
different between CKD 2 given NaHCO3 and FþV. These
latter data support that dietary acid reduction was the greater
contributor to decreased tubulo-interstitial injury in CKD 2
than Sys BP reduction, and further support the greater role of
acid retention in mediating tubulo-interstitial injury.
UTGF, a possible mediator of hypertensive nephropathy,12
decreased significantly among all three CKD 1 groups and the
net decrease was not significantly different among groups.
These data suggest that dietary acid reduction had no
measurable UTGF effect in CKD 1, and that lower Sys BP in
FþV compared with the remaining CKD 1 groups also did
not additionally affect UTGF. Because all groups underwent 6
months of aggressive BP reduction before entering the
protocol,25 sustained effects of this BP reduction might have
reduced UTGF similarly in all three CKD 1 groups.26 Similar
to UNAG, UTGF increased in CKD 2 without intervention
but UTGF decreased significantly in CKD 2 patients given
NaHCO3 and FþV, and the net UTGF decrease between the
two interventions to reduce dietary acid was not different.
These latter data support the fact that reduced dietary acid
decreased UTGF and, similar to the data described for
UNAG, the lower Sys BP in CKD 2 given FþV compared
with NaHCO3 appears not to have been additive after 30
days. Dietary acid reduction decreased Ualdo in humans with
moderately reduced eGFR in this and previous studies,14 and
did so in animals with moderately reduced GFR.7 Because
aldosterone increases UTGF in animals,27 reduced kidney
aldosterone might mediate decreased UTGF in response to
dietary acid reduction. Furthermore, because there was no
significant difference in net UTGF decrease among CKD 1,
because UTGF increased without intervention in CKD 2 but
not in CKD 1, and because the net decrease in UTGF was not
significantly different after dietary acid reduction with FþV
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and HCO3 in CKD 2, despite Sys BP reduction in FþV but
not HCO3, the data support that acid retention present in
CKD 2, and not in CKD 1,14 more importantly mediates
increased UTGF in CKD 2 than Sys BP.
Both dietary acid reduction interventions decreased UET
and Ualdo in CKD 2 but not in CKD 1. Because UET and
Ualdo are respective surrogates of their kidney levels in
animals with and without reduced GFR,7,22 these data
support the fact that dietary acid reduction decreased kidney
ET-1 and aldosterone levels in CKD 2 but not in CKD 1.
Because the increased kidney ET-1 and aldosterone levels in
animals with reduced GFR are mediated by retained acid due
to decreased GFR7,13 and CKD 2 subjects appear to have
retained acid,14 these data support the fact that decreased
retained acid mediated the decrease in UET and Ualdo
induced by dietary acid reduction. Given that endothelins
and aldosterone mediate kidney injury in animals with
reduced GFR and that decreasing their levels ameliorates
kidney injury,7,22 decreased kidney ET-1 and aldosterone
levels likely contributed to the reduction in kidney injury
associated with reduced dietary acid.
Table 3 shows that although the net UET decrease was
similar between CKD 2 subjects given NaHCO3 and FþV,
Ualdo decrease was statistically significantly greater in CKD 2
patients given NaHCO3 than in those given FþV. Although
each intervention reduced dietary acid as evidenced by
reduced urine NAE, the NaHCO3 intervention was accom-
panied by increased Naþ intake without additional Kþ
intake. On the other hand, the FþV intervention was
accompanied by reduced Naþ intake and increased Kþ
intake. These two factors would be expected to promote
greater Ualdo reduction in NaHCO3 than in FþV. The
greater Ualdo reduction in NaHCO3 versus FþV subjects
might be expected to lead to greater reduction in kidney
injury in NaHCO3 versus FþV CKD 2 subjects, given animal
studies that support a role for aldosterone, in addition to
ET-1, in mediating kidney injury and GFR decline in animals
with partial nephrectomy.7 Nevertheless, and as indicated
earlier, changes in the three parameters of kidney injury
support comparable reduction of kidney injury in CKD 2
subjects given NaHCO3 and FþV. The observation that
greater Ualdo reduction induced by NaHCO3 than FþV was
not accompanied by a greater reduction of kidney injury
parameters in CKD 2 subjects given NaHCO3 might be
explained, at least in part, by stable Sys BP during the
1-month follow-up in the NaHCO3 subjects as compared
with a significant reduction in Sys BP in the FþV subjects.
Consequently, CKD2 subjects given NaHCO3 might have had
a greater decrease in kidney injury parameters if their Sys BP
was similarly reduced. On the other hand, greater kidney
injury reduction might become evident in the CKD 2 subjects
given NaHCO3 with a longer follow-up. Additional and
longer-term studies will be needed to address this issue.
In summary, these studies support the fact that kidney
injury increased without dietary acid reduction and show
that 30 days of dietary acid reduction with NaHCO3 or FþV
reduced kidney injury in subjects with CKD stage 2 eGFR due
to hypertensive nephropathy. The present studies also show
that FþV, but not NaHCO3, reduced Sys BP, suggesting a
possible advantage of FþV as a strategy to reduce dietary
acid for kidney protection. These studies encourage longer-
term studies to determine whether FþV, similar to NaHCO3,
is an effective adjunct to Sys BP reduction and angiotensin-
converting enzyme inhibition in slowing GFR decline in
hypertensive and possibly other nephropathies.
MATERIALS AND METHODS
This interventional study compared the effect of 30 days of reduced
dietary acid with added daily oral NaHCO3 (HCO3) or added FþV
on urine parameters of kidney injury in subjects with macro-
albuminuric CKD (urine albumin-to-creatinine ratio 4200mg/g
Cr) due to hypertensive nephropathy and stage 1 (490ml/min,
CKD 1) or stage 2 (60–90ml/min, CKD 2) eGFR by MDRD
formula.28 Primary outcome was the effect of these interventions
on urine excretion of the following parameters of kidney injury:
Ualb as a general marker of progressive kidney injury,10 UNAG as a
marker of kidney tubulo-interstitial injury11 and because it reflected
kidney injury induced by dietary acid in experimental model of
CKD,5,22 and transforming growth factor b (UTGFV) because it also
reflected kidney injury induced by dietary acid in an experimental
model of CKD22 and because it might be a mediator of hypertensive
nephropathy.12 Secondary outcomes were the effects of these
interventions on UET and Ualdo, two mediators of dietary acid-
induced kidney injury and GFR decline in an animal model of CKD
without metabolic acidosis.7 We excluded subjects with metabolic
acidosis (plasma TCO2o24.5mmol/l, the lower limit of normal for
our laboratory).
The protocol is outlined in Figure 4. Three groups of CKD1 and
CKD 2 were studied. (1) A total of 26 CKD 1 and 40 CKD 2 subjects
received oral NaHCO3 at a concentration of 0.5mEq/kg/day for 30
days (HCO3) as scored tablets containing 10mEq NaHCO3 with
sucrose. Each subject was prescribed tablets to the nearest one-half
tablet by body weight in kg (for example, a 70 kg subject received 3.5
tablets daily); (2) A total of 26 CKD 1 and 40 CKD 2 subjects
received an amount of FþV, free of charge to reduce their dietary
acid by 50%, focusing primarily on FþV that are particularly base-
inducing.9 Fruits such as apples, apricots, oranges, peaches, pears,
raisins, and strawberries were predominantly provided. Vegetables
such as carrots, cauliflower, eggplant, lettuce, potatoes, spinach,
tomatoes, and zucchini were predominantly provided. Subjects did
not receive specific dietary instructions and were allowed to
integrate the added FþV into their ad lib diets as they wished.
Dietary acid was measured before and after interventions using
3-day diaries of food intake and a published formula.9 The necessary
amount of FþV was prescribed by a dietician and distributed from
a community center food bank used by all FþV subjects. To assure
that each FþV subject received sufficient FþV, we provided the
described amount for each member of the household; (3) A total of
27 CKD 1 and 40 CKD 2 subjects had no intervention (Time
Control). Otherwise, all subjects were allowed to eat ad lib. Other
inclusion criteria were as follows: (1) non-malignant hypertension;
(2) 60XeGFRo90ml/min for CKD 2, 490ml/min for CKD 1; (3)
X2 primary care physician visits in the preceding year, showing
compliance with clinic visits; (4) age X18 years and able to give
consent. Exclusion criteria were as follows: (1) primary kidney
disease or findings consistent thereof such asX3 red blood cells per
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high-powered field of urine or urine cellular casts; (2) history of
diabetes or fasting blood glucose X110mg/dl; (3) history of
malignances, chronic infections, pregnancy, or clinical evidence
of cardiovascular disease; and (4) peripheral edema or diagnoses
associated with edema such as heart/liver failure or nephrotic
syndrome. The diagnosis of hypertensive nephropathy as the
exclusive nephropathy cause was made clinically by excluding
subjects with systemic diseases associated with nephropathy,
nephrotic-range proteinuria, and urine abnormalities other than
albuminuria. None had a kidney biopsy. Secondary causes of
hypertension such as renal artery stenosis and hyperaldosteronism
were excluded clinically. Kidney Doppler studies and plasma
aldosterone-to-renin ratios were not carried out. Subjects were
recruited as described.4 All had had their Sys BP reduced toward a
target ofo130mmHg using a previously described protocol25 with
regimens including angiotensin-converting enzyme inhibitors as
recommended for hypertensives with albuminuria.29
Eight-hour (0800 to 1600 h) urine NAE (8 h NAE) was measured
and calculated from urine titratable acidity, ammonium (NH4
þ ),
and HCO3 ([NH4
þ ]þ [titratable acidity][HCO3]) as described
earlier4 at baseline and 30 days after the intervention. Sys BP and
venous plasma acid–base parameters, ET-1, and aldosterone were
measured at baseline and after the intervention. Urine excretion of
albumin, NAG, TGF, ET-1, aldo, Naþ , and Kþ were each measured
before and after intervention in a morning urine specimen and
factored per gram of Cr.
Our IRB approved the protocol.
Analytical methods
Plasma and urine Cr and urine albumin were measured using the
Sigma Diagnostics Creatinine Kit (Procedure No. 555, Sigma
Diagnostics, St Louis, MO).30 The IRMA SL Series 2000 blood
analysis system (Edison, NJ) measured venous plasma/blood pH and
plasma CO2. Urine and plasma TCO2 were measured using
ultrafluorometry.31 Urine titratable acidity was measured by
correction to the ambient plasma pH by NaOH addition, and
NH4
þ by the Formalin titrametric (to ambient plasma pH)
method.32 Plasma ET and urinary ET were measured with an RIA
kit (Peninsula Laboratories, Belmont, CA) after extraction using
Bound Elut C18 columns (Varian, Harbor City, CA).13 Plasma and
urine aldosterone were measured after extraction with Bound Elut
C18 columns (Varian) using a radioimmunoassay kit (Diagnostic
Products Corporation, Los Angeles, CA) as performed previously.7
Urine ET and aldosterone excretion were expressed per gram Cr of a
spot AM specimen.
Statistical methods
Patient characteristics at the time of study enrollment were tabulated
by percentages or described by mean and standard deviation. We
first compared the baseline characteristics among the six subject
groups with the w2-test or the one-way analysis of variance, as
appropriate. The primary outcomes were Ualb, UNAG, and UTGF
in response to 30 days of oral FþV or NaHCO3. Secondary
outcomes included plasma ET, plasma aldo, Ualdo, urine 8 h NAE,
and venous TCO2. The changes from pre to post for each group
were described by mean and s.d., and they were considered with a
one-sample t-test. The differences among the three groups within
CKD cohort were considered with one-way analysis of variance
followed by post-hoc Tukey’s test. In addition, outcomes were
compared between a group in CKD 1 and a corresponding CKD 2
group with a two-sample t-test. A P-value of less than 0.05 indicates
a statistical significance. SAS version 9.2 (SAS Institute, Cary, NC)
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Urine+serum
parameters
Urine+serum
parameters
Urine+serum
parameters
Urine+serum
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Time Control
30 days 30 days 30 days 30 days
0.5 meq/kg.bw
NaHCO3
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vegetablesTime Control
Urine+serum
parameters
Urine+serum
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Figure 4 |Outline of the protocol to test the effect after 30 days on parameters of kidney injury of no intervention (Time Control),
daily oral NaHCO3 at a concentration of 0.5 mEq/kg bw/day, or fruitsþ vegetables given in amounts designed to reduce
dietary acid intake by 50%.
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was used for the statistical analysis and graphs were created using R
2.12.1 (R Core Development Team, 2010).
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